The FDA has granted Fast Track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.
The F8 formulation is 8 times more concentrated than Egrifta and 2 times more concentrated than the current F4 formulation, Egrifta SV.
Licensing criteria should be equitable, nondiscriminatory, objective, and compatible with similar risks in other populations.
HealthDay News — A high proportion of women seem to undergo mammography screening every year, despite recommendations for biennial screening, according to a research letter published in the Annals of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results